Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study by Barlesi, Fabrice, Prof, Vansteenkiste, Johan, Prof, Spigel, David, MD, Ishii, Hidenobu, MD, Garassino, Marina, MD, de Marinis, Filippo, MD, Özgüroğlu, Mustafa, Prof, Szczesna, Aleksandra, MD, Polychronis, Andreas, PhD, Uslu, Ruchan, MD, Krzakowski, Maciej, Prof, Lee, Jong-Seok, Prof, Calabrò, Luana, MD, Arén Frontera, Osvaldo, MD, Ellers-Lenz, Barbara, MS, Bajars, Marcis, MD, Ruisi, Mary, MD, Park, Keunchil, Prof

Get full text

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study by Hui, Rina, Prof, Özgüroğlu, Mustafa, Prof, Villegas, Augusto, MD, Daniel, Davey, MD, Vicente, David, MD, Murakami, Shuji, MD, Yokoi, Takashi, MD, Chiappori, Alberto, MD, Lee, Ki Hyeong, MD, de Wit, Maike, Prof, Cho, Byoung Chul, Prof, Gray, Jhanelle E, MD, Rydén, Anna, PhD, Viviers, Louis, MD, Poole, Lynne, MSc, Zhang, Yiduo, PhD, Dennis, Phillip A, MD, Antonia, Scott J, MD

Get full text

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study by Agarwal, Neeraj, Prof, McQuarrie, Kelly, BSN, Bjartell, Anders, Prof, Chowdhury, Simon, MD, Pereira de Santana Gomes, Andrea J, MD, Chung, Byung Ha, Prof, Özgüroğlu, Mustafa, Prof, Juárez Soto, Álvaro, MD, Merseburger, Axel S, MD, Uemura, Hirotsugu, Prof, Ye, Dingwei, Prof, Given, Robert, Prof, Cella, David, Prof, Basch, Ethan, Prof, Miladinovic, Branko, PhD, Dearden, Lindsay, MSc, Deprince, Kris, MD, Naini, Vahid, PharmD, Lopez-Gitlitz, Angela, MD, Chi, Kim N, Prof

Get full text

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-... by Özgüroğlu, Mustafa, Prof, Kilickap, Saadettin, Prof, Sezer, Ahmet, Prof, Gümüş, Mahmut, Prof, Bondarenko, Igor, Prof, Gogishvili, Miranda, MD, Nechaeva, Marina, MD, Schenker, Michael, Prof, Cicin, Irfan, Prof, Ho, Gwo Fuang, Prof, Kulyaba, Yaroslav, MD, Zyuhal, Kasimova, MD, Scheusan, Roxana-Ioana, MD, Garassino, Marina Chiara, Prof, He, Xuanyao, PhD, Kaul, Manika, MD, Okoye, Emmanuel, MPH, Li, Yuntong, PhD, Li, Siyu, PhD, Pouliot, Jean-Francois, PhD, Seebach, Frank, MD, Lowy, Israel, MD, Gullo, Giuseppe, MD, Rietschel, Petra, MD

Get full text

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, contr... by Bamias, Aristotelis, Prof, Davis, Ian D, Prof, Galsky, Matthew D, Prof, Arranz, José Á, MD, Kikuchi, Eiji, Prof, Grande, Enrique, MD, del Muro, Xavier Garcia, MD, Park, Se Hoon, Prof, De Giorgi, Ugo, MD, Alekseev, Boris, MD, Mencinger, Marina, MD, Izumi, Kouji, MD, Schutz, Fabio A, MD, Puente, Javier, MD, Li, Jian-Ri, MD, Panni, Stefano, MD, Gumus, Mahmut, Prof, Özgüroğlu, Mustafa, Prof, Mariathasan, Sanjeev, PhD, Poloz, Yekaterina, PhD, Bene-Tchaleu, Fabiola, MSc, Lee, Chooi, MD, Bernhard, Sandrine, PharmD, De Santis, Maria, MD

Get full text

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial by André, Fabrice, Prof, O'Regan, Ruth, Prof, Ozguroglu, Mustafa, Prof, Toi, Masakazu, Prof, Xu, Binghe, Prof, Jerusalem, Guy, Prof, Masuda, Norikazu, MD, Wilks, Sharon, MD, Arena, Francis, MD, Isaacs, Claudine, Prof, Yap, Yoon-Sim, MD, Papai, Zsuzsanna, MD, Lang, Istvan, Prof, Armstrong, Anne, MD, Lerzo, Guillermo, MD, White, Michelle, MD, Shen, Kunwei, Prof, Litton, Jennifer, MD, Chen, David, PhD, Zhang, Yufen, PhD, Ali, Shyanne, Taran, Tetiana, MD, Gianni, Luca, Dr

Get full text